BusinessHemispherx Biopharma Announces Identification of High Responder Patient Subgroup from Ampligen® Phase III Trial in Patients with CFS/MEBy Nasdaq OMXOct 31, 2016, 12:31 PM UTC
BusinessHemispherx Biopharma Announces Completion of Ampligen® Manufacturing Technology Transfer MilestoneBy Nasdaq OMXOct 19, 2016, 12:30 PM UTC
BusinessHemispherx Biopharma Regains Compliance with NYSE MKT Continued Listing StandardsBy Nasdaq OMXSep 19, 2016, 12:30 PM UTC
BusinessHemispherx Biopharma to Present Data on the Activity of Ampligen® Against Cancer at CHI’s 4th Annual Immuno-Oncology Summit, August 29 through September 2, 2016 in Boston, MABy Nasdaq OMXAug 29, 2016, 12:30 PM UTC
BusinessHemispherx Biopharma Announces Major Breakthrough: Approval for Commercial Sale of Rintatolimod (U.S. Tradename: Ampligen®) to Treat Severe Cases of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) in the Argentine RepublicBy Nasdaq OMXAug 26, 2016, 12:30 AM UTC
BusinessHemispherx Biopharma Retains Huron Consulting Group to Support Partnering Strategy and Planning for Alferon® and Ampligen®By Nasdaq OMXApr 20, 2016, 12:30 PM UTC
BusinessHemispherx Biopharma Enters into Alfa-n3 Interferon Clinical Trial, Sales, Marketing, Distribution, and Supply Agreement with Saudi Arabia’s Premier Pharma Company in Fight Against the Deadly MERS DiseaseBy Nasdaq OMXApr 4, 2016, 12:30 PM UTC
BusinessHemispherx Biopharma Announces Financial Results for the Year Ended December 31, 2015By Nasdaq OMXMar 29, 2016, 9:41 PM UTC
